TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
| Revenue (TTM) | $668.47M |
| Gross Profit (TTM) | $392.35M |
| EBITDA | $115.63M |
| Operating Margin | 12.50% |
| Return on Equity | 36.30% |
| Return on Assets | 4.33% |
| Revenue/Share (TTM) | $19.47 |
| Book Value | $14.96 |
| Price-to-Book | 5.82 |
| Price-to-Sales (TTM) | 4.42 |
| EV/Revenue | 5.1 |
| EV/EBITDA | 26.20 |
| Quarterly Earnings Growth (YoY) | -55.80% |
| Quarterly Revenue Growth (YoY) | 20.70% |
| Shares Outstanding | $34.68M |
| Float | $33.56M |
| % Insiders | 3.64% |
| % Institutions | 103.19% |
Volatility is currently contracting
ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, Aug. 21, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TMDX and any ticker you trade — then tracks every position and per-strategy win rate.
